For example, one study demonstrated how engineered EVPs, containing therapeutic siRNA, could target glioma cells by expressing a protein that binds to neuropilin-1 (NRP-1), which is recognized for its overexpression on the surface of these cells (Jia et al., 2018). This evidence concerns the gene NRP1 and glioma.